What is the current stock price of Pharming Group N.V. (PHARM.AS)?

As of the latest market data, Pharming Group N.V. (PHARM.AS) is trading at $0.00. The stock has seen a loss of undefined% today.

Does Pharming Group N.V. (PHARM.AS) pay a dividend?

Based on current data, Pharming Group N.V. does not have a confirmed active dividend policy.

What is the market cap of Pharming Group N.V.?

The current market capitalization of Pharming Group N.V. (PHARM.AS) is approximately unavailable.

PHARM.AS

Pharming Group N.V.·Healthcare

0.00

0.000%(+0.00)

Market Closed

Last Updated: — ET

52W L: $0.0052W H: $0.00

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Sector